Study summary · research use only
Humanin improves bone health in a glucocorticoid-treated mouse model of Duchenne muscular dystrophy
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
In this mouse study (male mdx mice, models B10.mdx and D2.mdx, glucocorticoid-treated), the authors tested whether the mitochondrial peptide humanin (HNG) affected glucocorticoid-induced growth retardation and osteoporosis, treating mice from 5 to 9 weeks of age. D2.mdx, but not B10.mdx, showed decreased bone growth and impaired bone structure versus wild type, and lower endogenous humanin expression than D2.WT. Glucocorticoid treatment was associated with growth retardation and reductions in cortical bone area, thickness, and mineral content. Co-administration with HNG was associated with prevention of bone growth impairment after one week of treatment and reduced glucocorticoid effects on cortical bone in B10.mdx mice. Adding HNG did not worsen skeletal muscle pathology and had a mild enlarging effect on muscle fibers. The authors state further studies are needed on dosing and long-term effects.
Abstract
Duchenne muscular dystrophy (DMD) is a progressive muscle disease for which glucocorticoid (GC) treatment is standard therapy. Patients typically suffer from short stature and osteoporosis, caused by the underlying disease and adverse effects of GCs. We investigated whether the mitochondrial peptide humanin (HNG) could prevent GC-induced growth retardation and osteoporosis in mouse models of DMD. Male mdx mice (B10.mdx and D2.mdx) were treated with GCs, with/without HNG, from 5 to 9 weeks of age using two different treatment regimens. Tibial growth was monitored by weekly X-ray imaging; growth plates analyzed with immunohistochemistry and histomorphometry; and bone structure examined using peripheral quantitative computed tomography. Effects on skeletal muscle were evaluated by immunohistochemistry, qPCR, and ex vivo force measurements. D2.mdx, but not B10.mdx, showed decreased bone growth and impaired bone structure compared with wild type (WT). D2.mdx also displayed increased growth plate height with lower endogenous humanin expression than D2.WT. GC treatment caused growth retardation and reductions in cortical bone area, thickness, and mineral content. Co-administration with HNG prevented bone growth impairment at one week of treatment and mitigated GC adverse effects on cortical bone in B10.mdx mice. Adding HNG to GCs did not exacerbate skeletal muscle pathology; in fact, HNG had a mild enlarging effect on muscle fibers. These data suggest that HNG is a potential candidate for improving bone health in DMD during GC therapy. Further in vivo studies are needed to determine optimal HNG dosing and to assess the effects of long-term treatment on skeletal muscle function.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.